{"filings":[{"id":2322836,"accession_number":"0001628280-26-057617","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K/A","filed_at":"2026-08-18T18:03:52+00:00","items":["2.02","9.01","8.01"],"status":"ready","headline":"Iradimed Q2 revenue flat at $20.5M, EPS down 9% to $0.41; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20.5M, up 0.5% YoY; GAAP EPS $0.41, down 9%; non-GAAP EPS $0.46, down 7%.","Net income $5.2M, down 10% YoY; gross margin 74% vs 78% prior year.","Declares $0.20/share quarterly dividend, payable Aug 28, 2026, record Aug 14, 2026.","Reaffirms FY2026 guidance: revenue $91-96M, GAAP EPS $1.90-2.05, non-GAAP $2.09-2.24.","New 3870 MR IV pump launch underway; >70% of new pump orders for quad stack configuration."],"consensus_eps_estimate":0.4284,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":42444000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1977636,"accession_number":"0001628280-26-051240","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2026-07-31T12:15:40+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed Q2 revenue flat at $20.5M, EPS down; declares $0.20 dividend; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20.5M (+0.5% YoY); GAAP EPS $0.41 (down from $0.45); non-GAAP EPS $0.46 (down from $0.49).","Declared quarterly cash dividend of $0.20 per share, payable Aug 28, 2026 to holders of record Aug 14.","Reaffirmed FY2026 guidance: revenue $91-96M, GAAP EPS $1.90-2.05, non-GAAP EPS $2.09-2.24.","Launched next-gen 3870 MR IV pump; initial shipments met plan; domestic monitor unit bookings set record.","Q3 2026 guidance: revenue $23-24.5M, GAAP EPS $0.49-0.54, non-GAAP EPS $0.54-0.59."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1235596,"accession_number":"0001628280-26-045059","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2026-06-24T14:22:30+00:00","items":["5.07"],"status":"ready","headline":"Iradimed shareholders elect all five director nominees and approve auditor and say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Roger Susi, Monty Allen, Joe Kiani, Hilda Scharen-Guivel, James Hawkins with votes for ranging from 8.2M to 10.5M.","Ratified RSM US LLP as independent auditor for FY 2026 with 11,355,891 votes for, 8,716 against, 5,923 abstentions.","Advisory vote on named executive officer compensation approved: 10,487,387 for, 106,030 against, 17,519 abstentions, 759,594 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92099,"accession_number":"0001628280-26-029125","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).","Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.","Reaffirms FY 2026 guidance: revenue $91M-$96M; GAAP EPS $1.90-$2.05; non-GAAP EPS $2.06-$2.21.","Launched next-gen 3870 MRI-compatible IV infusion pump; early orders strong; Q2 shipments expected.","Operating cash flow $8.3M, up 93% YoY; gross margin improved to 77% from 76%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":21979000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102661,"accession_number":"0001104659-26-012356","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q4 revenue $22.7M, EPS $0.50; raises dividend to $0.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $22.7M (+17% YoY); GAAP diluted EPS $0.50 (+25%), non-GAAP $0.54 (+23%).","Full year 2025 revenue $83.8M (+14% YoY); GAAP diluted EPS $1.75 (+17%), non-GAAP $1.93 (+16%).","Quarterly dividend raised 18% to $0.20/share from $0.17, payable March 6, 2026 to holders of record Feb 23.","FY2026 guidance: revenue $91-96M, GAAP EPS $1.90-2.05, non-GAAP EPS $2.06-2.21.","Initial 3870 next-gen MRI pump shipped in Q4; full rollout begins Q1 2026 with meaningful H2 revenue contribution."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":83814000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118894,"accession_number":"0001104659-25-119090","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRadimed declares special cash dividend of $0.50 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special dividend of $0.50 per share payable Dec 30, 2025 to holders of record Dec 17, 2025.","Company cites $56.5M cash as of Q3 2025, driven by 17 straight quarters of record revenue.","CEO Roger Susi says board chose to return excess cash rather than hold beyond operational needs.","Dividend complements regular quarterly program; future declarations remain at board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118893,"accession_number":"0001104659-25-105298","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q3 revenue of $21.2M, up 16% YoY; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.43, non-GAAP diluted EPS $0.47; net income $5.6M (+10% YoY).","Full-year 2025 guidance raised: revenue $82.5M-$83.5M, GAAP EPS $1.68-$1.72, non-GAAP EPS $1.84-$1.88.","Declares quarterly dividend of $0.17/share, payable Nov 25, 2025, record date Nov 14, 2025.","Next-generation 3870 MRI-compatible IV pump on track for limited commercial shipments Dec 2025, full rollout Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":61122101.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135440,"accession_number":"0001558370-25-011834","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Iradimed appoints Masimo founder Joe Kiani to board; Anthony Vuoto retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Vuoto retired as director effective Aug 27, 2025; no disagreement with the company.","Joe Kiani, founder of Masimo and CEO of Willow Laboratories, appointed director effective Sep 2, 2025.","Kiani will serve on the Audit Committee and chair the Compensation Committee.","Board size remains at five directors after the transition.","Kiani receives standard non-employee director compensation as disclosed in the 2025 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135439,"accession_number":"0001558370-25-009933","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q2 revenue of $20.4M (+14% YoY), raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS of $0.45 (up 18% YoY); non-GAAP diluted EPS of $0.49 (up 17% YoY).","Declares regular quarterly cash dividend of $0.17 per share, payable Aug 28, 2025.","FY2025 revenue guidance raised to $80-82.5M; GAAP EPS to $1.60-1.70; non-GAAP EPS to $1.76-1.86.","Gross profit margin held at 78%; record backlog for pump and monitor products as of June 30, 2025.","Q3 2025 guidance: revenue $20.5-20.9M, GAAP EPS $0.41-0.45, non-GAAP EPS $0.45-0.49."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":39920037.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152428,"accession_number":"0001558370-25-008791","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iradimed shareholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Roger Susi (8.85M for), Monty Allen (9.54M), Anthony Vuoto (10.76M), Hilda Scharen-Guivel (10.80M), James Hawkins (8.38M).","Ratification of RSM US LLP as auditor for FY2025: 11,775,729 for, 10,385 against, 1,399 abstentions.","Advisory say-on-pay resolution approved: 10,777,171 for, 286,889 against, 13,963 abstentions, 709,490 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152427,"accession_number":"0001558370-25-008245","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRadimed receives FDA 510(k) clearance for next-gen MRidium 3870 infusion pump","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 510(k) clearance on May 29, 2025 for the MRidium 3870 IV Infusion Pump System.","Company remains the world's only supplier of non-magnetic MRI infusion pump devices (first device in 2005).","New pump features enhanced touchscreen UI, advanced safety, drug library, and four-channel capability.","Strategic rollout begins with initial units in Q4 2025; full commercial distribution ramps through 2026.","CEO Roger Susi says clearance is a milestone from FDA collaboration on evolving regulatory requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152426,"accession_number":"0001558370-25-006220","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed Q1 record revenue $19.5M (+11% YoY); EPS $0.37 GAAP, $0.42 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue of $19.5M, up 11% YoY from $17.6M; GAAP diluted EPS $0.37 (+16% YoY).","Non-GAAP diluted EPS $0.42 (+17% YoY); excludes $0.7M stock compensation net of tax.","Declared regular quarterly cash dividend of $0.17/share, payable May 30, 2025 to holders of record May 20.","Q2 2025 guidance: revenue $19.7-19.9M; GAAP EPS $0.37-0.40; non-GAAP EPS $0.41-0.44.","Reaffirms FY 2025 guidance: revenue $78-82M; GAAP EPS $1.55-1.65; non-GAAP EPS $1.71-1.81."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":19510637.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171256,"accession_number":"0001558370-25-000907","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED Q4 revenue $19.4M (+11% YoY); raises quarterly dividend to $0.17/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue record $19.4M (+11% YoY); GAAP EPS $0.40, non-GAAP EPS $0.44.","Full year 2024 revenue $73.2M (+12% YoY); GAAP EPS $1.50, non-GAAP EPS $1.66.","Quarterly dividend increased 13% to $0.17/share from $0.15; payable March 5, 2025.","FY2025 guidance: revenue $78-82M, GAAP EPS $1.55-1.65, non-GAAP EPS $1.71-1.81.","New Orlando facility on track for mid-2025 completion; ~$5.5M capex remaining in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":73242121.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171255,"accession_number":"0001558370-25-000117","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.","Full-year 2024 revenue ~$73.1M-$73.3M vs $65.6M in 2023, YoY growth 11-12%.","Orders booked in Q4 exceeded shipments, building robust backlog for 2025.","CEO Roger Susi cites increasing demand expected to continue through 2025.","Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":73242121.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188231,"accession_number":"0001558370-24-014005","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.","Raises FY 2024 GAAP EPS guidance to $1.49-$1.52 (from $1.37-$1.47) and Non-GAAP to $1.64-$1.67 (from $1.52-$1.62).","Declares regular quarterly cash dividend of $0.15/share, payable Nov 25, 2024 to holders of record Nov 15, 2024.","Q3 cash flow from operations was $9.1M, vs $1.4M in prior year; new Orlando facility capex ~$9M remaining.","Q4 2024 guidance: revenue $18.8M-$19.2M, GAAP EPS $0.39-$0.42, Non-GAAP EPS $0.42-$0.45."],"consensus_eps_estimate":null,"consensus_eps_actual":1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":53852954.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204719,"accession_number":"0001558370-24-010533","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q2 revenue $17.9M, GAAP EPS $0.38","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $17.9M, up 11.2% YoY; operating income $5.6M, up 13.4%.","GAAP diluted EPS $0.38; non-GAAP diluted EPS $0.42 vs $0.36 in Q2 2023.","Q3 2024 guidance: revenue $18.0-18.2M, GAAP EPS $0.34-0.37.","FY 2024 reaffirmed: revenue $72-74M, GAAP EPS $1.37-1.47.","Declares quarterly dividend $0.15/share payable Aug 30, record Aug 20."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":35526995.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221572,"accession_number":"0001558370-24-009354","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iradimed stockholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Roger Susi (9,119,299 for), Monty Allen (9,709,115), Anthony Vuoto (10,720,742), Hilda Scharen-Guivel (10,741,229), James Hawkins (8,771,444).","Ratification of RSM US LLP as independent auditor for FY2024: 11,609,434 for, 13,044 against, 2,073 abstentions.","Advisory vote on executive compensation approved: 10,684,897 for, 197,682 against, 32,812 abstentions; 709,160 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221571,"accession_number":"0001558370-24-008988","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"IRADIMED uplists to Nasdaq Global Market, trading starts June 14, 2024 under IRMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq approved transfer from Capital Market to Global Market, effective June 14, 2024.","Ticker remains 'IRMD'; no stockholder action required.","CEO Roger Susi highlights continued growth and enhanced visibility from higher listing standards.","Nasdaq Global Market includes ~1,450 companies with stricter financial and governance requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221570,"accession_number":"0001558370-24-008847","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IRADIMED extends headquarters lease by one year to May 2025 in related-party deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended to May 31, 2025, with possible month-to-month holdover through Nov 2025.","Monthly base rent set at $34,133, adjusted annually for CPI; company pays insurance and maintenance.","Landlord SUSI, LLC is controlled by CEO/President/Chairman Roger Susi, making this a related-party transaction.","Company waived its second five-year renewal option under the original lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221569,"accession_number":"0001558370-24-006460","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.","GAAP diluted EPS $0.32, non-GAAP $0.36; net income $4.1M, +21.4%.","Declared regular quarterly dividend of $0.15/share payable May 30, 2024 to holders of record May 20.","Q2 2024 guidance: revenue $17.6-17.8M, GAAP EPS $0.33-0.36, non-GAAP $0.36-0.39.","FY 2024 guidance reiterated: revenue $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":17598119.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241106,"accession_number":"0001558370-24-000877","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q4 revenue $17.5M (+17.4%); initiates quarterly dividend; FY24 guidance $72-74M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 2023 revenue $17.5M (+17.4% YoY); GAAP diluted EPS $0.36 vs $0.29, non-GAAP $0.39 vs $0.32.","Full-year 2023 revenue $65.6M (+23% YoY); GAAP EPS $1.35, non-GAAP EPS $1.48; operating income $20.0M (+28.2%).","Guidance Q1 2024: rev $17.0-17.3M, GAAP EPS $0.29-0.31, non-GAAP $0.33-0.35. FY2024: rev $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62.","CEO announces initiation of a quarterly dividend in 2024 (amount and record date not specified in release).","Operating cash flow for FY2023 $13.5M vs $10.0M; expects ~$13M capex for new Orlando facility in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":65562296.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258585,"accession_number":"0000898432-23-000856","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iradimed initiates $0.15 quarterly dividend and $0.48 special cash dividend","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special dividend of $0.48 per share (~$6.1M); quarterly dividend of $0.15 per share (~$1.9M) initiated.","First quarterly and special dividend payable Jan 12, 2024 to holders of record Dec 22, 2023.","Quarterly dividend implies annual rate of $0.60 per share (~$7.6M per annum).","Company commits ~$20M to expand production capacity; ~$7M spent on land and initial construction.","Board notes strong performance as rationale; evaluating financing for remainder of expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258584,"accession_number":"0001558370-23-017757","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Iradimed adopts clawback policy for executive compensation recovery effective Oct 2, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Board adopted Incentive-Based Compensation Recovery Policy on Nov 2, 2023, effective Oct 2, 2023.","Policy mandates recovery of erroneously awarded incentive-based compensation from current and former executive officers.","Recovery triggered by an accounting restatement; no misconduct required for clawback.","Policy complies with Nasdaq Rule 5608 and SEC Rule 10D-1; indemnification of executive officers prohibited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258583,"accession_number":"0001558370-23-017501","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q3 revenue $16.5M, raises FY GAAP EPS guidance to $1.34-$1.37","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $16.5M (+23% YoY); GAAP diluted EPS $0.40 vs $0.27 YoY; non-GAAP diluted EPS $0.43 vs $0.29 YoY.","Operating income $5.9M, up 43% YoY; ninth consecutive quarterly revenue record led by monitoring business up 40% QoQ.","Q4 2023 guidance: revenue $16.9M-$17.4M; GAAP EPS $0.35-$0.38; non-GAAP EPS $0.38-$0.41.","Full-year 2023 guidance raised: revenue $65.0M-$65.5M; GAAP EPS $1.34-$1.37 (up from prior); non-GAAP EPS $1.48-$1.51.","Cash flow from operations $3.5M in Q3 ($9.6M YTD) vs $2.4M ($7.0M YTD) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":48110120.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275884,"accession_number":"0001558370-23-013067","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q2 revenue of $16.1M, raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $16.1M (+25% YoY); GAAP diluted EPS $0.33 vs $0.26; non-GAAP EPS $0.36 vs $0.26.","Operating income $5.0M, up 19% YoY; 8th consecutive record revenue quarter.","Monitoring devices revenue grew 25% YoY to $6.1M; IV pump systems up 17% to $4.5M.","FY2023 guidance raised: rev $64.5-$65.5M, GAAP EPS $1.25-$1.28, non-GAAP EPS $1.37-$1.40.","Q3 2023 guidance: rev $16.1-$16.3M, GAAP EPS $0.33-$0.35, non-GAAP EPS $0.36-$0.38."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":31605480.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293506,"accession_number":"0001558370-23-011142","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iradimed shareholders elect all five director nominees, approve equity plan and charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roger Susi, Monty Allen, Anthony Vuoto, Hilda Scharen-Guivel, James Hawkins elected to board (vote ranges: 7.9M-10.9M for).","Ratified RSM US LLP as auditor for FY2023 (11,617,623 for, 8,816 against).","Advisory say-on-pay approved (10,782,715 for, 133,595 against).","Approved 2023 Equity Incentive Plan (8,665,347 for, 2,251,481 against).","Approved charter amendment limiting officer liability (10,139,697 for, 779,087 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293505,"accession_number":"0000898432-23-000278","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iradimed named to Forbes 2023 America's Best Small Companies list","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Iradimed recognized as one of Forbes' top 100 small companies for 2023.","Forbes screened over 1,000 firms with market cap $300M-$2B; ranking based on earnings, sales growth, ROE, and stock return.","CEO Roger Susi highlighted team dedication and commitment to delivering patient safety devices and shareholder value.","Company is a leader in non-magnetic IV infusion pumps and vital signs monitors for MRI environments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293504,"accession_number":"0001558370-23-007985","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q1 revenue $15.5M; raises FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $15.5M (+25.7% YoY); GAAP diluted EPS $0.27, non-GAAP $0.30.","Operating income $4.0M, up 30% YoY; gross margin 75.7% vs 76.2%.","Paid special dividend of $1.05 per share during Q1.","Q2 2023 guidance: revenue $15.6-15.8M, non-GAAP EPS $0.30-0.32.","FY 2023 guidance raised: revenue $62-63.5M, non-GAAP EPS $1.26-1.35."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":15475083.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314138,"accession_number":"0000898432-23-000052","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO Roger Susi adopts 10b5-1 plan to sell IRMD shares daily through Dec 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Roger Susi entered into a 10b5-1 plan on Feb 6, 2023 for daily sales of shares starting Feb 13, 2023.","Plan runs until Dec 31, 2023 or earlier completion/termination; subject to minimum price threshold.","Sales will be disclosed via Form 4 filings; purpose is to increase public float in a non-dilutive manner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314137,"accession_number":"0000898432-23-000046","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"iRadimed reinstates land purchase, acquires 26.5 acres in Florida for $6.2M for new manufacturing facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased ~26.518 acres in Orange County, FL for $6.2M from O Property, Ltd.","Reinstated previously terminated Nov 2022 purchase agreement; closing occurred Jan 31, 2023.","Aggregate earnest money of $250k non-refundable except if seller fails to perform.","Property planned for medical device design and manufacturing facility (manufacturing expansion)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314136,"accession_number":"0000898432-23-000037","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q4 revenue $14.9M (+25% YoY); declares special $1.05 dividend; FY23 guidance $61-63M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $14.9M (vs $11.9M Q4 2021); GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.32.","Full-year 2022 revenue $53.3M (vs $41.8M FY2021); GAAP EPS $1.02; non-GAAP EPS $1.10.","Board declared special cash dividend of $1.05/share, payable Feb 21, 2023 to holders of record Feb 13, 2023.","FY 2023 guidance: revenue $61-63M, GAAP EPS $1.10-1.20, non-GAAP EPS $1.23-1.34; Q1 2023 revenue $14.6-14.9M.","Cash and equivalents $57.9M, no debt; gross margin 77.4% for full year 2022 (up from 76.6%)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":53303145.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314135,"accession_number":"0000898432-23-000021","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed reports preliminary Q4 revenue $14.9M (+25% YoY); issues FY2023 guidance $61M-$63M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 preliminary revenue $14.9M, up 25% YoY, above guidance of $14.1M-$14.8M.","Sixth consecutive quarterly revenue record; orders exceeded shipments, increasing backlog.","FY2023 guidance: revenue $61M-$63M, GAAP EPS $1.10-$1.20, non-GAAP EPS $1.23-$1.34.","Q1 2023 guidance: revenue $14.6M-$14.9M, GAAP EPS $0.23-$0.25, non-GAAP EPS $0.26-$0.28.","Full year 2022 revenue grew 27.5% over 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":53303145.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332572,"accession_number":"0000898432-22-000634","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Iradimed agrees to buy 27.19 acres in Florida for $7.3M for new facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price of $7.3M for approximately 27.19 acres of land in Orange County, FL.","Earnest money deposits total $250,000; $125,000 initial plus $125,000 additional after inspection.","Intended use: medical device design and manufacturing facility with future development.","Seller is O Property, Ltd.; transaction expected to close 30 days after 45-day inspection period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332571,"accession_number":"0000898432-22-000631","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q3 revenue up 23% to $13.4M; GAAP EPS $0.27; guides Q4 rev $14.1-14.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $13.4M (+23% YoY), operating income $4.1M (+32%), GAAP EPS $0.27 (+35%).","Non-GAAP net income $3.7M (excl. $0.3M stock comp); nine-month non-GAAP EPS $0.78 vs $0.50.","Gross margin improved to 78.6% from 77.1%; operating cash flow $3.9M in Q3.","Q4 guidance: revenue $14.1-14.8M, GAAP EPS $0.23-0.28, non-GAAP EPS $0.25-0.30.","CEO cites strong bookings and backlog; purchased 27 acres in Orlando for future HQ, tripling space."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":38439551.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332570,"accession_number":"0000898432-22-000616","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Iradimed withdraws 510(k) for MRidium 3870 pump; Q3 revenue $13.4M beats guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntarily withdrew 510(k) for MRidium 3870 Infusion Pump on Oct 5; plans to resubmit after FDA talks.","Preliminary Q3 revenue ~$13.4M, up 23% YoY, above guidance of $13.1–$13.3M.","Record quarterly revenue; fourth consecutive record quarter; orders exceeded shipments.","Domestic orders for current MRidium 3860 system were highest in three years.","CEO states withdrawal does not affect current revenue-generating product portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332569,"accession_number":"0000898432-22-000615","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iRadimed appoints Hilda Scharen-Guivel to Board of Directors, effective Oct 4, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to five directors; three are independent, including Scharen-Guivel.","Scharen-Guivel recently retired from FDA as Program Director of CDRH; 25+ years in federal agencies.","She will receive standard non-employee director compensation per 2022 proxy statement.","Scharen-Guivel has no material relationship with iRadimed; no transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350044,"accession_number":"0000898432-22-000500","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed reports record Q2 revenue of $12.7M; GAAP EPS $0.26; full-year guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $12.7M vs $9.8M YoY (+30%); GAAP diluted EPS $0.26 vs $0.12; non-GAAP EPS $0.26.","Q3 2022 guidance: revenue $13.1-13.3M, GAAP EPS $0.21-0.24, non-GAAP EPS $0.22-0.25.","Full-year 2022 guidance raised: revenue $52.5-53.2M (from $51.4-52.2M), GAAP EPS $0.89-0.95 (from $0.82-0.90), non-GAAP EPS $0.96-1.03.","Gross margin improved to 79.7% from 76.2%; domestic sales 85% of revenue.","Q2 cash from operations $1.6M vs $3.6M YoY; orders exceeded shipments building backlog."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":25032279.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367170,"accession_number":"0000898432-22-000401","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IRMD stockholders elect all four director nominees and approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Roger Susi, Monty Allen, Anthony Vuoto, and James Hawkins as directors; each received over 8M votes for.","Ratified RSM US LLP as independent auditor for FY2022 with 11.38M votes for, 9,204 against.","Advisory vote on executive compensation approved: 10.24M for, 139,607 against, 18,142 abstentions.","Advisory vote on frequency of say-on-pay: 10.29M favored every 1 year, 6,812 for 2 years, 96,160 for 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367169,"accession_number":"0000898432-22-000352","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iRadimed appoints John (Jack) Glenn as CFO effective June 20, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Salary $340,000/year, eligible for annual bonus of 50% of salary.","Receives restricted stock units valued at $750,000, vesting in four equal annual installments.","Prior CFO at Esko Bionics, Sonendo, and other medical device firms.","Glenn is brother-in-law of board member James Hawkins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367168,"accession_number":"0001104659-22-052778","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q1 revenue $12.3M (+33% YoY), EPS $0.20; raises FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $12.3M vs $9.2M YoY; GAAP diluted EPS $0.20 vs $0.11; non-GAAP EPS $0.22 vs $0.13.","Raised FY22 guidance: revenue $52.5-53.2M (prev $51.4-52.2M), GAAP EPS $0.89-0.95, non-GAAP EPS $0.96-1.03.","Q2 guidance: revenue $12.5-12.7M, GAAP EPS $0.21-0.23, non-GAAP EPS $0.23-0.25.","Paid special dividend of $1.00 per share during Q1 2022; monitors segment revenue surged to $5.19M from $2.60M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":12310710.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367167,"accession_number":"0000898432-22-000319","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iRadimed CFO/COO Resigns; Controller Named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Scott, CFO and COO, resigns effective May 27, 2022 to pursue other opportunities.","Matt Garner, Controller, appointed interim CFO effective April 28, 2022.","Garner to receive $50,000 bonus (grossed up to max $76,000) upon permanent CFO appointment.","Formal search for a new CFO has commenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386543,"accession_number":"0001104659-22-012765","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRadimed declares special $1.00 per share cash dividend","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special cash dividend of $1.00 per share declared by Board on Feb 5, 2022.","Payable Feb 24, 2022 to shareholders of record as of Feb 17, 2022.","Company cites cash balance of nearly $62M at end of 2021 as source.","CEO states excess cash beyond operational needs is being returned to shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386542,"accession_number":"0001104659-22-011698","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q4 revenue up 39% YoY to $11.9M; guides FY22 rev $51.4-52.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 GAAP diluted EPS $0.31 vs $0.05 YoY; non-GAAP diluted EPS $0.33 vs $0.07.","Full-year 2021 revenue $41.8M (+32% YoY); full-year GAAP EPS $0.74 vs $0.11.","Gross profit margin improved to 77.9% in Q4 vs 75.3% YoY; free cash flow $10.8M for FY.","FY2022 guidance: revenue $51.4M-$52.2M, GAAP EPS $0.82-$0.90; Q1 rev $12.1M-$12.3M.","Record bookings growth: Q4 bookings +48% YoY, FY bookings +39% YoY, signaling strong demand."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":41814581.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404467,"accession_number":"0000898432-21-000732","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2021-11-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO Roger Susi enters new 10b5-1 plan to sell shares over 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan replaces prior June 2021 plan; allows daily sales from Nov 22, 2021 to Nov 21, 2022.","Sales subject to minimum market price threshold; executed shares disclosed via Form 4 filings.","Purpose: increase public float in a non-dilutive manner.","Plan terminates on earlier of Nov 21, 2022, full execution, or termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404466,"accession_number":"0001104659-21-131410","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q3 revenue up 42% to $10.9M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2021 revenue $10.9M (+42% YoY); GAAP diluted EPS $0.20, non-GAAP $0.23.","Full-year 2021 guidance raised: revenue $41.4-41.6M, GAAP EPS $0.60-0.61, non-GAAP $0.70-0.71.","Gross profit margin improved to 77.1% from 74.6% in Q3 2020; domestic sales 79.5% of revenue.","Nine-month operating cash flow $7.9M vs $3.3M; free cash flow $7.5M vs $3.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":29941721.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423462,"accession_number":"0001104659-21-097921","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2021-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q2 2021 revenue $9.8M, GAAP EPS $0.12; guides FY21 rev $40.0-40.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2021 revenue $9.8M, up 44% YoY from $6.8M; net income $1.5M vs net loss of $2.1M.","GAAP diluted EPS $0.12; non-GAAP diluted EPS $0.14, up from $0.05 in Q2 2020.","Q3 2021 guidance: rev $10.3-10.5M, GAAP EPS $0.14-0.15, non-GAAP EPS $0.16-0.17.","Full-year 2021 guidance: rev $40.0-40.4M, GAAP EPS $0.53-0.55, non-GAAP EPS $0.60-0.62.","Cash and investments $56.1M at quarter-end; operating cash flow $4.5M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":19034419.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423461,"accession_number":"0000898432-21-000566","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2021-07-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Iradimed promotes Chris Scott to CFO and COO with new employment agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Scott appointed Chief Financial and Operating Officer effective July 8, 2021.","Base salary of $360,000/year; annual bonus target 60% of salary.","Immediate RSU grant of $150,000 vesting over four years.","Annual equity target of $400,000 under incentive plan.","Severance: 12 months base salary for without cause/good reason; 18 months for change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}